Cargando…

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

BACKGROUND: Patient-reported outcomes (PROs) might detect more toxic effects of radiotherapy than do clinician-reported outcomes. We did a quality of life (QoL) substudy to assess PROs up to 24 months after conventionally fractionated or hypofractionated radiotherapy in the Conventional or Hypofract...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilkins, Anna, Mossop, Helen, Syndikus, Isabel, Khoo, Vincent, Bloomfield, David, Parker, Chris, Logue, John, Scrase, Christopher, Patterson, Helen, Birtle, Alison, Staffurth, John, Malik, Zafar, Panades, Miguel, Eswar, Chinnamani, Graham, John, Russell, Martin, Kirkbride, Peter, O'Sullivan, Joe M, Gao, Annie, Cruickshank, Clare, Griffin, Clare, Dearnaley, David, Hall, Emma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lancet Pub. Group 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664817/ https://www.ncbi.nlm.nih.gov/pubmed/26522334 http://dx.doi.org/10.1016/S1470-2045(15)00280-6

Ejemplares similares

Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)
por: Staffurth, John N., et al.
Publicado: (2021)

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
por: Dearnaley, David, et al.
Publicado: (2016)

Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial
por: Murray, Julia, et al.
Publicado: (2019)

Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial
por: Tree, Alison, et al.
Publicado: (2022)

Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity
por: Naismith, O.F., et al.
Publicado: (2019)

A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer
por: Murray, Julia, et al.
Publicado: (2020)

Linking CHHiP prostate cancer RCT with GP records: A study proposal to investigate the effect of co-morbidities and medications on long-term symptoms and radiotherapy-related toxicity
por: Lemanska, Agnieszka, et al.
Publicado: (2017)

Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation
por: Wilkins, Anna, et al.
Publicado: (2023)

Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial
por: Brand, Douglas H., et al.
Publicado: (2021)

Linkage of the CHHiP randomised controlled trial with primary care data: a study investigating ways of supplementing cancer trials and improving evidence-based practice
por: Lemanska, Agnieszka, et al.
Publicado: (2020)

Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer
por: Wilkins, Anna, et al.
Publicado: (2018)

Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL)
por: Dearnaley, David, et al.
Publicado: (2019)

PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018)
por: Syndikus, Isabel, et al.
Publicado: (2020)

The Role of Hypofractionated Radiotherapy in Prostate Cancer
por: Benjamin, Linus C., et al.
Publicado: (2017)

PEARLS – A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA‐avid pelvic and/or para-aortic lymph nodes at presentation
por: Murray, Julia, et al.
Publicado: (2022)

Clinical outcomes of hypofractionated radiotherapy for thyroid-associated ophthalmopathy
por: Lee, Sang Min, et al.
Publicado: (2020)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Review of Hypofractionated Radiotherapy for Prostate Cancer
por: Spyropoulou, Despina, et al.
Publicado: (2012)

Cost Minimization Analysis of Hypofractionated Radiotherapy
por: Yaremko, Hannah L., et al.
Publicado: (2021)

Hypofractionated Radiotherapy in African Cancer Centers
por: Swanson, William, et al.
Publicado: (2021)

Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone
por: Zambatis, Charalambos, et al.
Publicado: (1998)

Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity
por: Thomson, David, et al.
Publicado: (2012)

Hypofractionated stereotactic radiotherapy for large arteriovenous malformations
por: Wang, Huan-Chih, et al.
Publicado: (2012)

Hypofractionated External-Beam Radiotherapy for Prostate Cancer
por: Cho, L. Chinsoo, et al.
Publicado: (2013)

Image Fusion for Radiosurgery, Neurosurgery and Hypofractionated Radiotherapy
por: Inoue, Hiroshi K, et al.
Publicado: (2015)

Hypofractionated whole breast radiotherapy: current perspectives
por: Koulis, Theodora A, et al.
Publicado: (2015)

Hypofractionated radiotherapy to treat acne keloidalis nuchae
por: Kwan, Jennifer Yin Yee, et al.
Publicado: (2021)

Similar Outcomes of Standard Radiotherapy and Hypofractionated Radiotherapy Following Breast-Conserving Surgery
por: Hou, Hai-Ling, et al.
Publicado: (2015)

Accuracy and Reproducibility of Conformal Radiotherapy using Data from a Randomised Controlled Trial of Conformal Radiotherapy in Prostate Cancer (MRC RT01, ISRCTN47772397)
por: Stanley, S., et al.
Publicado: (2008)

Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer
por: Huddart, Robert, et al.
Publicado: (2021)

Hypofractionated Stereotactic Radiotherapy for Patients with Intracranial Meningiomas: impact of radiotherapy regimen on local control
por: Meniai-Merzouki, F., et al.
Publicado: (2018)

Comparison of Treatment Outcome between Hypofractionated Radiotherapy and Conventional Radiotherapy in Postmastectomy Breast Cancer
por: Tovanabutra, Chokaew, et al.
Publicado: (2020)

Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer
por: Yamazaki, Hideya, et al.
Publicado: (2021)

Protocol for hypofractionated adaptive radiotherapy to the bladder within a multicentre phase II randomised trial: radiotherapy planning and delivery guidance
por: Hafeez, Shaista, et al.
Publicado: (2020)

Hypofractionated Radiotherapy as Local Hemostatic Agent in Advanced Cancer
por: Rasool, Malik Tariq, et al.
Publicado: (2011)

Hypofractionated radiotherapy has the potential for second cancer reduction
por: Schneider, Uwe, et al.
Publicado: (2010)

Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib
por: Lewitzki, Victor, et al.
Publicado: (2015)

Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer
por: Crane, Christopher H.
Publicado: (2016)

Automated prediction of dosimetric eligibility for hypofractionated prostate radiotherapy
por: Lausch, Anthony, et al.
Publicado: (2017)

Hypofractionated radiotherapy in children with diffuse intrinsic pontine glioma
por: Hayashi, Akiko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o71b0ebbjevucup76uvmts24q8